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During JID’s year of the patient, comorbidity is 
an important and appropriate subject for con-
sideration. In its simplest form, comorbidity 
refers to the prevalence of two conditions in the 
same patient at frequencies that are higher than 
would be expected by chance alone. In 2002, 
some 15,000 deaths were considered to be 
directly attributable to skin diseases (Weinstock 
and Chren, 2008). If skin diseases have signifi-
cant comorbidities and fatalities, the numbers 
of deaths associated with such diseases may be 
even higher, pointing to an increased role for 
the dermatologist in the overall health of his or 
her patients. Forty years ago, Shuster and Marks 
(1970) delineated many of the systemic metabolic 
effects associated with extensive skin conditions, 
especially erythroderma. Seventy years ago, John 
H. Stokes, in his presidential address at the third 
annual meeting of the Society for Investigative 
Dermatology (SID), discussed the complexity of 
casual concepts (Stokes, 1940). Contemporary 
investigators are defining and struggling with 
these complexities. Geriatricians are interested in 
comorbidity because of the higher-than-expected 
concurrence of diseases in the aging population 
(Guralnik and Ferrucci, 2009).
Access to large administrative databases has 
enabled epidemiologists and dermatoepidemiolo-
gists to identify severe long-term vascular and car-
diovascular consequences of psoriasis, the most 
widely studied disease for potential comorbidities 
(e.g., Gelfand et al., 2006; Gelfand et al., 2010). 
In approaching the study of any condition and its 
comorbidities in order to establish comorbidity 
associations, there are several common steps:
• Repeating epidemiological studies in many 
population groups.
• Confirming studies with data in prospectively 
studied populations. This process is not trivial, 
considering the number of patients and 
the duration of study necessary to establish 
comorbidities.
• Ensuring that cause, effect, and confounding 
variables are all considered in the analyses.
• Considering cause and effect and 
“reverse causation,” using a Mendelian 
randomization approach when appropriate 
(Ebrahim and Smith, 2008; Thanassoulis and 
O’Donnell, 2009).
• Having a plausible biological mechanism(s).
• Presenting the data in a meaningful fashion 
for physicians (such as numbers needed to 
treat formulations to reduce one death).
• Determining, with randomly controlled 
intervention (prevention) studies, whether 
comorbidities can be decreased (this is 
the ultimate goal following the analytical 
studies).
The SID has been interested in comorbidity 
for several years and has made tangible commit-
ments to increasing awareness of comorbidity 
of skin diseases and encouraging comorbidity 
research through the following activities:
• The first free-standing SID comorbidity 
conference in 2008 brought together 
researchers in dermatology, epidemiology, 
cardiology, and pharmacology to 
present data and discuss skin diseases 
and comorbidities associated with 
psychiatric diseases, cardiac diseases, and 
chemotherapeutic drugs (Schultz, 2009).
• The second SID comorbidity session at the 
SID’s 2009 annual meeting in Montreal 
emphasized the detailed epidemiological 
processes required for outstanding 
comorbidity research.
• The third SID and American Academy of 
Dermatology comorbidity session at the SID 
2010 annual meeting in Atlanta emphasized 
the role that genome-wide association 
studies may have in defining risk factors 
for comorbidity, newer ways of collecting 
data directly from patients online, therapies 
for addressing comorbidities, and progress 
in defining the systemic nature of many 
skin diseases. Using input from patients 
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and their families, new ways of delivering medical 
and dermatology care and enhancing physician and 
patient education were considered, as were the changes 
necessary to define optimal and complete patient care.
The April 2010 issue of JID featured articles addressing 
whether psoriasis is an independent risk factor in acute 
ischemic heart disease; a study from the Netherlands is 
accompanied by two commentaries discussing the meth-
odological issues involved when considering psoriasis as a 
risk factor for cardiovascular disease (Wakkee et al., 2010; 
Gelfand et al., 2010; Stern, 2010). A related article shows the 
challenges in determining the clinical severity of psoriasis 
that may be important in stratifying cardiovascular risk stud-
ies (Spuls et al., 2010).
These recent articles indicate that concern about comorbidi-
ty will not be going away; instead, it will be defined with higher 
degrees of precision, and preventive protocols will have to be 
developed by investigators who are aware of the complexity of 
the issues involved. Mendelian randomization studies may be 
an important methodology to approach questions of cause and 
effect when applied to comorbidity studies.
Concluding thoughts
Is comorbidity a fad, or will it be an important component 
of patient-oriented medicine? I think the latter. PubMed lists 
more than 53,000 citations related to comorbidity (as of 15 
April 2010). More pragmatically, 990 funded grants in the 
National Institutes of Health (NIH) RePORT system include 
comorbidity as a key word (15 April 2010). Forty-four 
funded NIH grants have the word ”comorbidity” in their 
titles, indicating a serious commitment of investigators to 
the topic. Most interestingly, almost three-quarters of those 
grants were from institutes in which behavior is a major 
component of study (the National Institute of Mental Health, 
the National Institute on Drug Abuse, and the National 
Institute on Alcohol Abuse and Alcoholism); historically, 
comorbidity studies came out of the psychiatry and men-
tal health fields, and these disciplines show both the most 
interest and the most success in securing NIH funding for 
comorbidity studies. Studying comorbidity requires diverse 
talents, including knowledge of epidemiology, clinical dis-
eases, and biology, the exact talents necessary to improve 
human health based on robust data and to guide the direc-
tion of future health sciences studies.
Lowell A. Goldsmith
Editor Emeritus
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